Viagra maker Viatris misses revenue estimates on weak demand for older drugs

Drugmaker Viatris (VTRS.O) narrowly missed first-quarter revenue estimates on Thursday, hurt by weak sales for its older drugs such as cholesterol medication Lipitor and Norvasc for high blood pressure.
Net sales in its branded drugs unit, which makes up two-thirds of the company's total revenues, also fell 4.5% to $2.31 billion.